Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer.

Trial Profile

Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 May 2016

At a glance

  • Drugs Amrubicin (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 08 Oct 2010 Results have been presented at the 35th Congress of the European Society for Medical Oncology (ESMO).
    • 07 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top